PGEN: Held by 2 Biotech Hedge Funds (2026) | BiotechEdge

Precigen Inc.

PGEN

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase2 readout (PRGN-2012 - Phase I; Dose Level 1): Jun 2024. Short interest: 20.5% of float.

Share

BiotechnologyCEO: Helen SabzevariIPO: 2013Website ↗

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 370,847Value: $1,223,795.1Price: $3.30

PGEN | Director Sale — Mixed Signal

Kirk Randal J sold 370K shares at $3.30 (full position likely liquidation), timing ahead of near-term Phase I readout (PRGN-2012, due June 5). Sale could reflect profit-taking on run-up or lack of conviction in RRP indication; the larger Phase II combo readout (cervical cancer + Pembrolizumab) isn't until 2028, limiting near-term catalyst upside. Monitor whether other insiders hold through June readout.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 426,199Value: $1,406,456.7Price: $3.30

PGEN | Director Sell Signal - Lukewarm

Kirk Randal divested 426K shares at $3.30 (full position exit likely), a material sale but timing is ambiguous—the near-term Phase 1 readout (PRGN-2012, ~6 weeks out) could support either pre-catalyst de-risking or simple portfolio rebalancing. The 2028 cervical cancer catalyst is too distant to inform this decision. Monitor whether other insiders follow or if management commentary on PRGN-2012 suggests confidence concerns.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 38,976Value: $128,620.8Price: $3.30

Director Kirk Randal sold ~39K shares at $3.30, representing a modest ~$129K position reduction that lacks timing significance relative to near-term catalysts—the Phase I RRP readout is 3 months away and the cervical cancer combo readout is 3+ years out. The sale size and price point suggest portfolio rebalancing rather than conviction shift. Monitor for additional insider moves closer to the June 2024 RRP readout.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 1,108,998Value: $3,659,693.4Price: $3.30

PGEN - Director Sale Signal

Kirk Randal sold ~1.1M shares at $3.30 (full position liquidation likely) ahead of near-term Phase I readout (PRGN-2012, due June 5, 2024). The timing—sale just before data—suggests low confidence in near-term results, though the Phase II cervical cancer combo (PRGN-2009 + Pembrolizumab) readout is years away and provides downside cover for narrative reasons. Monitor whether other insiders follow or if the Phase I miss is material to valuation.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 152,063Value: $501,807.9Price: $3.30

PGEN: Director Selling Ahead of Near-Term Readout

Director Kirk Randal divested ~152k shares (~$502k) at $3.30, notable timing given the PRGN-2012 Phase I readout expected in ~2 weeks (6/5/24). While director sales can reflect diversification/liquidity needs rather than conviction shifts, the proximity to a near-term catalyst warrants caution; insider buying would signal confidence, but selling into an imminent data event does not. The 2028 cervical cancer readout is too distant to factor into this signal.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 50,797Value: $167,630.1Price: $3.30

PGEN | Director Sale - Neutral Signal

Kirk Randal sold 50,797 shares at $3.30, a modest position reduction (~$168K) ahead of near-term Phase I readout (PRGN-2012, due June 5, 2024). The sale timing suggests either portfolio rebalancing or caution on near-term catalysts, though the relatively small size and distance to the 2028 cervical cancer readout limit conviction on negative bias. Execution price and volume warrant monitoring for follow-on insider activity.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 168,794Value: $557,020.2Price: $3.30

PGEN | Insider Sale Signal

Director Kirk Randal divested 168,794 shares (~$557K) at $3.30, representing a material reduction ahead of a near-term Phase 1 readout (PRGN-2012, RRP, due June 5). The timing is notable given the clinical inflection point is <2 weeks away—a typical blackout/selling window for insiders confident in avoiding downside surprises, though non-committal on upside. Longer-dated cervical cancer catalyst (2028) offers limited near-term catalyst support.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 47,101Value: $155,433.3Price: $3.30

PGEN | Director Sale - Neutral Signal

Kirk Randal sold ~47K shares at $3.30, a modest position reduction (~$155K) that lacks obvious negative timing—the near-term Phase I readout (PRGN-2012) is just weeks away (6/5/24). Sale magnitude and price don't suggest conviction in downside; likely routine rebalancing or liquidity need rather than catalyst front-running.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 23,789Value: $78,503.7Price: $3.30

PGEN | Director Sale - Modest Conviction Signal

Kirk Randal J sold ~23.8K shares at $3.30, a relatively small position reduction (~$78.5K) that doesn't suggest loss of confidence ahead of the near-term Phase I readout (PRGN-2012 expected June 5, 2024). The timing is neutral; sale occurs well ahead of clinical data, limiting bearish inference. No accompanying insider buys or halt of selling program observed.

KIRK RANDAL JDirectorSaleMar 31, 2026SEC Filing →

Shares: 2,334,420Value: $7,703,586Price: $3.30

PGEN | Director Sale - Neutral Signal

Kirk Randal sold ~$7.7M (2.3M shares) at $3.30, representing a substantial position reduction absent obvious catalyst timing—the nearest readout (PRGN-2012) is 5+ months out. Sale size and lack of proximity to near-term data suggest portfolio rebalancing or liquidity needs rather than pre-catalyst risk-off; monitor for additional insider transactions ahead of June 2024 readout as a true sentiment indicator.